EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Decision regret in older adults with advanced cancer receiving systemic therapy: Associations with patient‐reported and clinician‐rated tolerability metrics

Marie A Flannery iD, Zhihong Zhang, Eva Culakova, Kah Poh Loh, Beverly Canin, Rachael G Tylock, Fiona A Stauffer iD, Mostafa Mohamed iD, Hongying Sun iD, Supriya Mohile

Cancer · 2025

DOI: 10.1002/cncr.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Marie A Flannery und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Decision Making, Emotions, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Decision regret (DR) (distress or remorse after a treatment decision) has received limited examination in older adults with advanced cancer. The authors hypothesized that DR would change over time and be associated with worse patient‐reported outcomes (PRO) and clinician‐rated tolerability metrics over 6 months.

Methods

Adults aged 70+ with advanced cancer planning to receive systemic treatment were recruited from a national trial (GAP70+, NCT02054741). DR level (none (0), mild [1–25], and moderate/severe [>25]) and PROs (symptoms, functional status, and satisfaction with treatment) were assessed at 4–6 weeks, 3 months, and 6 months after treatment initiation and compared with ANOVA. Associations between clinician‐rated grade >3 toxicities, and treatment‐related hospitalizations and DR were examined with longitudinal linear mixed modeling.

Results

Data from 623 patients (M = 77 years, 43% female, mixed diagnoses) who completed the DR scale at least once were analyzed. At 4–6 weeks, mean DR was 17.1 (SD = 15.7), with 50% reporting mild DR and 21% moderate/severe DR. Patients experiencing higher DR reported significantly higher concurrent symptom severity, lower functional scores, and lower treatment satisfaction (all p < .05). At 6 months, mean DR was 3.9 points higher (95% confidence interval [CI], 1.1–6.7, p = .006) in patients with any grade >3 toxicities and 6.8 points higher (95% CI, 3.4–10.2, p < .001) in patients with treatment‐related hospitalization.

Conclusions

DR changes over time and is associated with worse PROs and clinician‐rated toxicity. Clinicians can discuss DR and poor tolerability in conversations about high‐risk cancer treatment with older adults who have advanced cancer. Clinical Trials Registration NCT02054741

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Decision MakingEmotionsNeoplasmsAgedAged, 80 and overFemaleHumansMalePatient Reported Outcome MeasuresRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

advanced cancerdecision regretolder adultpatient‐reported outcomestreatment tolerability

Autor:innen und Institutionen

  • School of Nursing, University of Rochester Medical Center, Rochester, New York, USA.
  • University of Rochester Medical Center alumni, Rochester, New York, USA.
  • Department of Medicine, Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
  • Patient Advocate and Board Member, University of Rochester Medical Center and NIH Tolerability Consortium, Rochester, New York, USA.
  • Public Health Sciences, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
  • Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.

ORCID-Profile: Marie A Flannery, Fiona A Stauffer, Mostafa Mohamed, Hongying Sun

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIA NIH HHS
  • National Cancer Center

Zitieren

APA

Flannery, M. A., Zhang, Z., Culakova, E., Loh, K. P., Canin, B., Tylock, R. G., Stauffer, F. A., Mohamed, M., Sun, H., & Mohile, S. (2025). Decision regret in older adults with advanced cancer receiving systemic therapy: Associations with patient‐reported and clinician‐rated tolerability metrics. Cancer. https://doi.org/10.1002/cncr.70023

Vancouver

Flannery MA, Zhang Z, Culakova E, Loh KP, Canin B, Tylock RG, et al. Decision regret in older adults with advanced cancer receiving systemic therapy: Associations with patient‐reported and clinician‐rated tolerability metrics. Cancer. 2025. doi:10.1002/cncr.70023

BibTeX
@article{Flannery2025,
  author = {Flannery, Marie A and Zhang, Zhihong and Culakova, Eva and Loh, Kah Poh and Canin, Beverly and Tylock, Rachael G and Stauffer, Fiona A and Mohamed, Mostafa and Sun, Hongying and Mohile, Supriya},
  title = {Decision regret in older adults with advanced cancer receiving systemic therapy: Associations with patient‐reported and clinician‐rated tolerability metrics},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70023}
}
Kostenlos starten →